This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
This is a short (127 pages) scholarly report concerning much that is known about polycythemic disorders today. It is based on the author's experience over three years in a multicenter study in the United States and subsequent prospective study of patients in Israel. While the neurologic manifestations and associations of polycythemic disorders are given no special consideration in this book, one notes that patients commonly present with headache, vertigo, dizziness, nervousness, paresthesias, blurred vision, and other symptoms of vascular disorder. Today approximately 10% of patients with polycythemia vera die of thrombo-hemorrhagic cerebrovascular complications. Although the frequency of thrombo-hemorrhagic events is much reduced by P-32 treatment during early years of the disease, this effect seems to be temporary. At eight years following diagnosis and thereafter, the frequency of thrombo-hemorrhagic disorders becomes similar, if not greater, than those of patients treated without radiation. Polycythemia associated with cerebellar hemangioblastoma is due to erythropoietic